Medication for High Triglycerides
For markedly elevated triglycerides (≥500 mg/dL), fibrates or niacin should be initiated before LDL-lowering therapy to prevent acute pancreatitis, followed by statin therapy once triglycerides are controlled. 1, 2
Treatment Algorithm Based on Triglyceride Level
Triglycerides ≥500 mg/dL (Severe Hypertriglyceridemia)
Primary goal: Prevent pancreatitis
- First-line therapy: Fibrates (fenofibrate or gemfibrozil) OR niacin 1, 2, 3
- Adjunctive therapy: Prescription omega-3 fatty acids (2-4 g/day) 3, 4
- After triglycerides controlled: Add statin therapy to address LDL-C and achieve non-HDL-C <130 mg/dL 1, 2
Critical lifestyle interventions:
- Very low-fat diet (10-15% of calories from fat) 4
- Complete alcohol abstinence 1, 3
- Eliminate added sugars 4
- Address secondary causes (diabetes control, hypothyroidism, medications) 3
Triglycerides 200-499 mg/dL (Moderate Hypertriglyceridemia)
Primary goal: Reduce ASCVD risk
First-line therapy: Statin (moderate to high intensity) 3, 5
If triglycerides remain elevated (150-499 mg/dL) on maximally tolerated statin AND patient has ASCVD or diabetes with elevated cardiovascular risk:
Alternative options (Class IIa, weaker evidence):
Target: Non-HDL-C <130 mg/dL 1, 3
Key Medication Details
Fibrates
- Mechanism: PPAR-α activators that reduce VLDL production
- Efficacy: Can lower triglycerides 30-50% 8
- Critical warning: When combining with statins, use fenofibrate (NOT gemfibrozil) and keep statin doses relatively low to minimize severe myopathy risk 1, 6
- Monitoring: Watch for myalgia, check CK if symptomatic 9
Icosapent Ethyl (Purified EPA)
- Dose: 4 g/day (2 g twice daily with meals)
- Evidence: REDUCE-IT trial showed 25% relative risk reduction in cardiovascular events 5, 7
- Indication: Patients with triglycerides 150-499 mg/dL on statin with ASCVD or diabetes plus ≥2 risk factors 6, 5
- Caution: Modest increase in atrial fibrillation risk 10
Niacin
- Efficacy: Lowers triglycerides and raises HDL-C
- Major limitation: Flushing limits adherence 9
- Evidence gap: Statin plus niacin has NOT shown cardiovascular benefit and may increase stroke risk 6
- Use: Consider primarily for severe hypertriglyceridemia when fibrates insufficient 1, 2
Omega-3 Fatty Acids (Mixed EPA/DHA)
- Dose: 2-4 g/day for triglyceride lowering 1, 3
- Evidence: Mixed EPA/DHA formulations have NOT shown cardiovascular benefit in trials 5
- Use: Adjunctive therapy for severe hypertriglyceridemia 3, 4
Critical Pitfalls to Avoid
Do NOT use bile acid sequestrants when triglycerides >200 mg/dL—they worsen hypertriglyceridemia 1, 11
Do NOT combine gemfibrozil with statins—use fenofibrate if combination needed 1, 6
Do NOT use dietary supplement niacin—only prescription niacin is appropriate 1
Do NOT add fibrates or niacin to statins for routine moderate hypertriglyceridemia—these combinations have not shown cardiovascular benefit 6, 5
Address secondary causes first: Optimize diabetes control, treat hypothyroidism, review medications (thiazides, beta-blockers, oral estrogens, antipsychotics, immunosuppressants) 3, 11
Emerging Therapies
Novel agents targeting apolipoprotein C-III (volanesorsen, olezarsen, plozasiran) and ANGPTL3 show profound triglyceride reductions (up to 80%) and are particularly promising for familial chylomicronemia syndrome 12, 10. These are not yet widely available but represent the future of severe hypertriglyceridemia management.
When to Hospitalize
Triglycerides ≥1,000 mg/dL with abdominal pain: Hospitalize for acute pancreatitis risk. Consider insulin infusion (with dextrose to prevent hypoglycemia) for rapid triglyceride reduction, plus fibrates 8, 13. Plasmapheresis may be needed if conservative management fails 7.